Comparison of the effectiveness of ERP and its combination with EMDR in cognitive components and OCD severity

Clinical trials of Eye Movement Desensitization and Reprocessing (EMDR) and Exposure / Response Prevention (ERP) in reducing the severity of symptoms and Improve cognitive components in patients with obsessive-compulsive disorder with life stressful experiences.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190319043090N2

Enrollment

Registered

2019-05-28

Start date

2018-02-09

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive- Compulsive Disorder. F40-F48 Neurotic, stress-related and somatoform disorders

Interventions

Intervention 1: Intervention group: Experimental group with pre / post test and follow-up :Intervention group 1: Implementation of the Eye Movement Desensitization and Reprocessing in combination with

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: The primary diagnosis of OCD is according to the DSM-5 criteria, which will be determined by the clinical-structured clinical interview of SCID-I by clinical psychologists and experienced psychiatrists who have been trained in OCD evaluation. Score Y-BOCS =16 If there is depression, the secondary is OCD Age range 18 to 60 years Patients will receive a standard dose of SSRIs throughout the course of treatment under the supervision of a psychiatrist Minimum IQ of 80 / or minimum education in secondary school 2 / or equivalent. Declaration of satisfaction regarding participation in the research project (complete written consent).

Exclusion criteria

Exclusion criteria: The presence of comorbidities in either now or in the past other than depression. Drugs abuse Enemy suicide attempt Psychiatric disorders due to medical conditions Personality disorders Receive simultaneously any psychological treatment currently for axis I disorders Dissatisfaction with the continuation and completion of the treatment process at each stage of the research

Design outcomes

Primary

Measure	Time frame
Severity of symptoms of obsessive- compulsive disorder. Timepoint: Pre-test pre-intervention-post-test after the completion of 13 sessions of therapy and follow up 3 months after the post-test stage. Method of measurement: Yale-Brown obsessive–compulsive scale (YBOCS).;Severity of symptoms of obsessive- compulsive disorder. Timepoint: Pre-test pre-intervention-post-test after the completion of 13 sessions of therapy and follow up 3 months after the post-test stage. Method of measurement: Yale-Brown obsessive–compulsive scale (YBOCS).;Cognitive Components of Obsessive-Compulsive Disorder. Timepoint: Pre-test pre-intervention-post-test after the completion of 13 sessions of therapy and follow up 3 months after the post-test stage. Method of measurement: Obsessive Beliefs Questionnaire(OBQ-44).	—

Measure

Time frame

Severity of symptoms of obsessive- compulsive disorder. Timepoint: Pre-test pre-intervention-post-test after the completion of 13 sessions of therapy and follow up 3 months after the post-test stage. Method of measurement: Yale-Brown obsessive–compulsive scale (YBOCS).;Severity of symptoms of obsessive- compulsive disorder. Timepoint: Pre-test pre-intervention-post-test after the completion of 13 sessions of therapy and follow up 3 months after the post-test stage. Method of measurement: Yale-Brown obsessive–compulsive scale (YBOCS).;Cognitive Components of Obsessive-Compulsive Disorder. Timepoint: Pre-test pre-intervention-post-test after the completion of 13 sessions of therapy and follow up 3 months after the post-test stage. Method of measurement: Obsessive Beliefs Questionnaire(OBQ-44).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Ebrahim Sarichloo

University of social welfare and rehabilitation sciences

mesarichloo@yahoo.com+98 28 3355 5054

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026